While growth stocks often show exceptional top-line acceleration and a mere promise of profitability further down the road, some young companies have already reached that mark. That's true for Veeva Systems (NYSE: VEEV) and Progyny (NASDAQ: PGNY). Both bring much-needed solutions to their respective healthcare niches -- plus profits for their shareholders.

Yet, today's volatile stock market has hammered their share prices. Could this be a good opportunity for investors to at least consider dollar-cost-averaging into these two stocks in 2022 and beyond? Let's take a look.

Veeva Systems offers life science companies an array of cloud solutions that run the gamut from clinical trial data management to marketing and customer relationship management tools. The company's two operating segments are R&D Solutions and Commercial Solutions, which respectively grew sales by 30% and 8% year over year in the latest quarter.

Continue reading

Source Fool.com